Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
China
/
Pharmaceuticals & Biotech
Create a narrative
WuXi AppTec Community
SHSE:603259 Community
3
Narratives
written by author
0
Comments
on narratives written by author
4
Fair Values set
on narratives written by author
Community Investing Ideas
WuXi AppTec
Popular
Undervalued
Overvalued
WuXi AppTec
AN
AnalystLowTarget
Consensus Narrative from 17 Analysts
Rising US-China Tensions And Overcapacity Will Curtail Prospects
Key Takeaways Geopolitical tensions and regulatory scrutiny threaten WuXi AppTec's client base, cost structure, and market positioning as global firms localize supply chains. Aggressive expansion and capital commitments increase exposure to demand slowdowns, risking underutilized assets and declining profitability as industry funding stagnates.
View narrative
CN¥89.70
FV
10.0% overvalued
intrinsic discount
10.12%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
5 days ago
author updated this narrative
WuXi AppTec
AN
AnalystHighTarget
Consensus Narrative from 17 Analysts
Global Demographic Shifts And Biotech Funding Will Fuel Outsourced R&D
Key Takeaways Strategic global expansion and late-stage project focus are set to drive resilient, above-trend revenue and margin growth while mitigating regulatory and geopolitical risks. Increased complexity in therapeutics and WuXi AppTec's integrated platform will deepen client reliance, enabling long-term earnings compounding and outsized profitability.
View narrative
CN¥138.00
FV
28.5% undervalued
intrinsic discount
17.04%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
WuXi AppTec
AN
AnalystConsensusTarget
Consensus Narrative from 17 Analysts
Aggressive Capacity Expansion Will Magnify Future Overvaluation Risks
Key Takeaways Sustained growth expectations and strong global pharma demand may be driving overly optimistic assumptions about margin expansion and future earnings resilience. Rising regulatory scrutiny, protectionism, and competition could threaten WuXi AppTec's addressable market, dampening long-term revenue and profit sustainability.
View narrative
CN¥106.50
FV
7.3% undervalued
intrinsic discount
13.48%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
15 days ago
author updated this narrative
Your Valuation for
603259
603259
WuXi AppTec
Your Fair Value
CN¥
Current Price
CN¥98.68
26.3% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
71b
2015
2018
2021
2024
2025
2027
2030
Revenue CN¥70.9b
Earnings CN¥26.7b
Advanced
Set Fair Value